Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with significant...

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its...

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...

menu
menu